title: Dramatic improvement following interleukin 1beta blockade in tumor necrosis factor receptor-1-associated syndrome (TRAPS) resistant to anti-TNF-alpha therapy.
authors.forename: Karim
authors.initials: K
authors.lastname: Sacré
authors.forename: Benoit
authors.initials: B
authors.lastname: Brihaye
authors.forename: Olivier
authors.initials: O
authors.lastname: Lidove
authors.forename: Thomas
authors.initials: T
authors.lastname: Papo
authors.forename: Marie-Annick
authors.initials: MA
authors.lastname: Pocidalo
authors.forename: Laurence
authors.initials: L
authors.lastname: Cuisset
authors.forename: Catherine
authors.initials: C
authors.lastname: Dodé
mesh_terms: D000328:Adult; D001327:Autoimmune Diseases / Q000188:drug therapy / Q000235:genetics; D002097:C-Reactive Protein / Q000187:drug effects; D010505:Familial Mediterranean Fever / Q000188:drug therapy / Q000235:genetics; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D053590:Interleukin 1 Receptor Antagonist Protein / Q000627:therapeutic use*; D053583:Interleukin-1beta / Q000037:antagonists & inhibitors*; D020125:Mutation, Missense / Q000235:genetics; D047888:Receptors, Tumor Necrosis Factor, Type I / Q000235:genetics*; D013577:Syndrome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D007155:Immunologic Factors; D053590:Interleukin 1 Receptor Antagonist Protein; D053583:Interleukin-1beta; D047888:Receptors, Tumor Necrosis Factor, Type I; D014409:Tumor Necrosis Factor-alpha; D002097:C-Reactive Protein